Advances in Neurodegenerative Diseases
Funding
Conflicts of Interest
References
- Mehta, A.R.; Chataway, J.; Pal, S.; Parmar, M.K.B.; Chandran, S. Trials for neurodegenerative diseases: Time to innovate. Lancet Neurol. 2021, 20, 984. [Google Scholar] [CrossRef]
- Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S.G.; Croteau, D.L.; Bohr, V.A. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 2019, 15, 565–581. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Siokas, V.; Dardiotis, E. Advances in Neurodegenerative Diseases. Neurol. Int. 2022, 14, 336. https://doi.org/10.3390/neurolint14020027
Siokas V, Dardiotis E. Advances in Neurodegenerative Diseases. Neurology International. 2022; 14(2):336. https://doi.org/10.3390/neurolint14020027
Chicago/Turabian StyleSiokas, Vasileios, and Efthimios Dardiotis. 2022. "Advances in Neurodegenerative Diseases" Neurology International 14, no. 2: 336. https://doi.org/10.3390/neurolint14020027
APA StyleSiokas, V., & Dardiotis, E. (2022). Advances in Neurodegenerative Diseases. Neurology International, 14(2), 336. https://doi.org/10.3390/neurolint14020027